Related references
Note: Only part of the references are listed.International consensus report on the investigation and management of primary immune thrombocytopenia
Drew Provan et al.
BLOOD (2010)
Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting Lymphocyte Count After 2 Doses Correlates With Survival
Geoffrey Y. Ku et al.
CANCER (2010)
Phase II Study of the Anti-Cytotoxic T-Lymphocyte-Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
Ki Y. Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical Development of the Anti-CTLA-4 Antibody Tremelimumab
Antoni Ribas
SEMINARS IN ONCOLOGY (2010)
Current systemic therapy for metastatic melanoma
Sanjiv S. Agarwala
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Neutropenia in a Patient Treated With Ipilimumab (anti-CTLA-4 Antibody)
Mojtaba Akhtari et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management
R. H. Aster et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Current management of metastatic melanoma
Van Anh Trinh
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2008)
Current concepts - Drug-induced immune thrombocytopenia
Richard H. Aster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Single-agent interleukin-2 in the treatment of metastatic melanoma: A systematic review
Teresa Petrella et al.
CANCER TREATMENT REVIEWS (2007)
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
AMM Eggermont et al.
EUROPEAN JOURNAL OF CANCER (2004)
Share Paper
